Gilead Acquires CymaBay: Liver Cure Leap?
Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to expand its liver disease portfolio, including access to potential treatment for ...
- Latest
- Trending
Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to expand its liver disease portfolio, including access to potential treatment for ...
AN2 Therapeutics voluntarily pauses enrollment in its epetraborole clinical trial due to lower efficacy. Safety is not a concern. The ...
John Flavin, CEO of life sciences VC firm Portal Innovations, discusses the importance of intertwining real estate investments with their ...
Vertical farming, the future of urban agriculture? Let's analyze its strengths, weaknesses, opportunities, and threats in this SWOT analysis.
Carle Health Methodist Hospital uses cutting-edge technology to detect lung cancer early, improving patient outcomes and saving lives. #LungCancerDetection
Discover how virtual reality and stationary bikes are offering promising relief for chronic pain. A study found that VR increased ...
Discover how surgeons are using real-time MRIs to enhance the safety and efficacy of gene therapy surgeries, revolutionizing the approach ...
Discover how artificial intelligence is revolutionizing the healthcare industry, improving diagnosis, enhancing patient engagement, and enabling proactive disease prevention. #AI ...
Discover the game-changing role of Artificial Intelligence (AI) in the field of Radiology, enhancing patient care at Regional Medical Imaging ...
The potential of AI in revolutionizing disease prevention and management and the challenges it faces in the healthcare system.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.